JMP Securities Maintains Market Outperform on BioAtla, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin maintains a Market Outperform rating on BioAtla (NASDAQ:BCAB) but lowers the price target from $12 to $5.
May 23, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JMP Securities analyst Reni Benjamin maintains a Market Outperform rating on BioAtla but lowers the price target from $12 to $5.
The lowered price target from $12 to $5 suggests a significant reduction in expected future performance, which could negatively impact investor sentiment in the short term despite the maintained Market Outperform rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100